on behalf of the GEM (Grupo Españ ol de MM)/PETHEMA (Programa para el Estudio de la Terapé utica en Hemopatías Malignas) cooperative study group Achieving complete remission (CR) in multiple myeloma (MM) translates into extended survival, but two subgroups of patients fall outside this paradigm: cases with unsustained CR, and patients that do not achieve CR but return into a monoclonal gammopathy of undetermined significance (MGUS)-like status with long-term survival. Here, we describe a novel automated flow cytometric classification focused on the analysis of the plasma-cell compartment to identify among newly diagnosed symptomatic MM patients (N ¼ 698) cases with a baseline MGUS-like profile, by comparing them to MGUS (N ¼ 497) patients and validating the classification model in 114 smoldering MM patients. Overall, 59 symptomatic MM patients (8%) showed an MGUS-like profile. Despite achieving similar CR rates after high-dose therapy/autologous stem cell transplantation vs other MM patients, MGUS-like cases had unprecedented longer time-to-progression (TTP) and overall survival (OS; B60% at 10 years; Po0.001). Importantly, MGUS-like MM patients failing to achieve CR showed similar TTP (P ¼ 0.81) and OS (P ¼ 0.24) vs cases attaining CR. This automated classification also identified MGUS patients with shorter TTP (P ¼ 0.001, hazard ratio: 5.53) and ultra-high-risk smoldering MM (median TTP, 15 months). In summary, we have developed a biomarker that identifies a subset of symptomatic MM patients with an occult MGUS-like signature and an excellent outcome, independently of the depth of response.
INTRODUCTION
Prolongation of patients' survival after the introduction of highdose therapy (HDT) and novel agents into the up-front treatment of multiple myeloma (MM) is now unquestionable. 1 However, the increment in response rates, 2, 3 life expectancy 4 and different treatment alternatives [5] [6] [7] [8] has also raised new questions, either related to the importance of the depth of remission achieved or specific treatment decisions (for example, timing for transplantation and duration of maintenance). 9 The importance of achieving complete remission (CR) after front-line therapy to extend progression-free survival is almost consensual, 10, 11 with two potential groups of patients justifying the lack of global agreement: those that show unsustained CR after treatment and are associated to a dismal outcome, and those that despite not achieving CR, experience long-term disease control. 12 Recent observations have shed some light about the prospective identification of patients at risk of showing unsustained CR (those cases with high-risk cytogenetics and persistent minimal residual disease), 13 whereas consistent data on patients failing to achieve CR but with an indolent disease course remains mostly restricted to a single study on the total therapy programs, which shows that cases with a monoclonal gammopathy of undetermined significance (MGUS)-like signature at baseline by gene expression profiling are associated with 410-year survival rates after HDT/autologous stem cell transplantation (ASCT) despite displaying a lower incidence of CR. 14 The prospective identification of this particular subgroup of MM patients may be of utmost clinical relevance in order to avoid overtreatment in patients that otherwise would have been considered as suboptimal responders; therefore, investigation of new biomarkers and easy to perform assays for routine diagnostic laboratories could potentially contribute to identify such MM patients.
Here, we investigate the potential utility of a multiparameter flow cytometry (MFC) immunophenotyping-computerized algorithm based on the simultaneous assessment of the tumor burden and the degree of clonality of the bone marrow (BM) plasma-cell 
PATIENTS AND METHODS

Patients and treatment
The study involved 698 newly diagnosed MM patients included in two consecutive PETHEMA/GEM trials: GEM2000 (VBMCP/VBAD followed by HDT/ASCT and 2 years of maintenance with interferon plus prednisone; N ¼ 486) 15 and GEM2005o65y (randomized induction with the same chemotherapy plus bortezomib in the last two cycles or thalidomide/ dexamethasone or bortezomib/thalidomide/dexamethasone followed by HDT/ASCT, and 3 years of maintenance with interferon-a2b or thalidomide or thalidomide/bortezomib; N ¼ 212). 16 Median follow-up was 71 months (range: 4-153 months). To investigate for an MGUS-like profile among patients with symptomatic MM, we have compared them with 497 MGUS patients. In addition, a series of 114 smoldering MM patients was used as a validation set. All cases (N ¼ 1309) were diagnosed according to the International Myeloma Working Group (IMWG) criteria, 17 and all samples were collected after informed consent was given; the study was approved by the local ethical committees.
MFC immunophenotypic studies
Erythrocyte-lysed whole BM samples were immunophenotyped using a four-color combination of the following fluorochrome-conjugatedfluorescein isothiocyanate, phycoerythrin, peridinin chlorophyll proteincyanin 5.5 (PerCPCy5.5) and allophycocyanin-monoclonal antibodies: CD38 CD56 CD19 CD45. PCs were initially identified on the basis of strong CD38 expression and intermediate side scatter signals. Clonal PCs were discriminated from normal PCs by aberrant phenotypic expressions, typically consisting of simultaneous downregulation of CD19 and CD45, with or without overexpression of CD56 (in around 2/3 of the cases).
For the remaining patients in whom CD45 was positively expressed, lack of CD19 and/or bright CD56 staining (equal or higher than that of natural killer cells) allowed identification of clonal PCs. 18 Data acquisition was performed in FACSCalibur and FACSCantoII flow cytometers (Becton Dickinson Biosciences, San Jose, CA, USA) using the FACSDiva 6.1 software (Becton Dickinson Biosciences), and a two-step acquisition procedure. In the first step, information about 5 Â 10 4 events corresponding to the whole-sample cellularity was stored; in the second step, data about CD38 þ gated events was selectively stored, for a minimum of 10 6 leukocytes/tube. Data analysis was performed using the Infinicyt software (Cytognos SL, Salamanca, Spain).
Generation of a computerized model based on MFC immunophenotypic analysis
The relative frequency of BM PCs plus the percentage of clonal and normal PCs within the whole BM PC compartment was determined for each patient. Subsequent principal component analysis (PCA) using these three variables was then performed and shown by the automatic population separator (APS; principal component 1 vs principal component 2) graphical representation of the Infinicyt software. 19 In this APS view, every patient becomes represented by a dot, and the first (x axis) and second (y axis) principal components are used to produce a bidimensional representation of patient profiles; each principal component is represented by a linear combination of the three parameters described above. 20 On the basis of this APS representation, MGUS and symptomatic MM patients were simultaneously grouped with each patient represented by a single dot and groups defined by 1.5 standard deviation (s.d.) median borders ( Figure 1 ).
Statistical analyses
The Mann-Whitney U-test was used to estimate the statistical significance of differences observed between groups. MGUS and smoldering MM patients who had not progressed were censored on the last date they were known to be alive and without progression. Overall survival (OS) was measured from the start of chemotherapy to the date of death or last visit. Time-to-progression (TTP) and OS curves were plotted by the KaplanMeier method, and the log-rank test was used to estimate the statistical significance of differences observed between curves. Cox stepwise regression (backward elimination) was used for multivariate analysis, retaining those variables with a statistically significant predictive value (Pp0.05) in the predictive model. For all statistical analyses, the SPSS software (version 15.0; SPSS Inc., Chicago, IL, USA) was used.
RESULTS
Identification of newly diagnosed symptomatic MM patients with an MGUS-like profile
A total of 59 patients with symptomatic MM (8%) were plotted in the APS graphical representation ( Figure 1 ) outside of their reference MM group (N ¼ 698) and inside the MGUS cluster (N ¼ 497), such cases were being thereby termed as MGUS-like from now on. All 59 patients had at least one CRAB feature (7% with increased Calcium, 3% with Renal insufficiency, 13% with Anemia and 92% with detectable Bone lesions). MGUS-like MM patients as compared with the other cases (Table 1) were characterized by a favorable clinical presentation with a higher frequency of International Staging System stage I or II (89% vs 75%; Po0.001), greater baseline hemoglobin levels (median of 123 vs 104 g/l, respectively; Po0.001), as well as lower tumor burden as assessed either by serum paraprotein levels (2.2 vs 4.0 g/dl; Po0.001), PCs by conventional morphology (10% vs 41% PCs; Po0.001) or by immunophenotyping (0.6% vs 12%, Po0.001). In addition, normal PCs within the total BM PC compartment were preserved (32% vs 0.3% of all BM PCs, Po0.001), and clonal PCs from MGUS-like MM patients were more quiescent (0.7% vs 1.2%; P ¼ 0.02). Age at presentation was similar between the two groups (median of 58 years). When comparing the phenotype of clonal PCs in the two groups of patients, only a trend toward lower frequency of CD81 þ clonal PCs in MGUS-like patients as compared with the other cases (20% vs 51%; P ¼ 0.06) (Table 2) . No significant differences were noted for PC DNA ploidy status. Regarding cytogenetic abnormalities, del(13q) was uncommon among MGUS-like MM patients (6% vs 45%; P ¼ 0.002), and there was also a trend for lower incidence of IGH translocations (18% vs 40%; P ¼ 0.06), particularly for those associated with high-risk disease ( Table 2) .
Outcome of newly diagnosed symptomatic MM patients with an MGUS-like profile We first investigated whether symptomatic MM patients with an MGUS-like profile at baseline were more likely to attain CR after HDT/ASCT as compared with the rest of the cases, but no significant differences were noted (50% vs 41%, respectively; P ¼ 0.21). However, MGUS-like MM patients did show a significantly superior TTP (median not reached (NR) vs 44 months, Po0.001; hazard ratio: 3.27; Figure 2a ) and OS (median NR vs 67 months, Po0.001, hazard ratio: 2.54; Figure 2b) . Notably, the 10-year estimate for TTP and OS in MGUS-like patients were 59% and 65%, respectively (Po0.001). As the superior outcome of MGUSlike MM cases was not foreseen by the rates of CR attained after HDT/ASCT, we then investigated if this model maintained its prognostic value among patients failing to achieve CR. Accordingly, among symptomatic MM cases who did NR CR, patients classified by the computerized algorithm as MGUS like at baseline also showed a superior TTP (median NR vs 38 months, Po0.001) and OS (median NR vs 54 months, P ¼ 0.003) than the other symptomatic MM cases. Moreover, when focusing exclusively on MGUS-like symptomatic MM patients, no significant differences for median TTP and OS were noted between cases in CR vs those that did not attain CR after HDT/ASCT (Figure 3) . By contrast, as could be expected, achieving CR among non-MGUS-like MM patients predicted for significantly (Po0.001) longer TTP and OS. It should be noted that around one-fourth (28%) of all MGUS-like MM patients were progression-free survival at 10 years (vs 4% of the other symptomatic MM cases; Po0.001).
Prediction of malignant transformation of MGUS patients by the MFC immunophenotypic-computerized algorithm When we applied the same MFC immunophenotypic classification model to MGUS cases, a few of these (7/497; 1%) were plotted outside of their reference group, clustering together with typical symptomatic MM (Figure 4) . These patients had a marked imbalance between clonal and normal PCs (99%-1%) similar to that found in symptomatic MM, and/or a relative high frequency of BM PCs by MFC (9 to 13%) although all had o10% by morphology; interestingly, three of these MGUS cases (43%) did progressed into symptomatic MM with a median TTP for this patient population of 85 months vs 234 months for the standard MGUS cases (P ¼ 0.001, hazard ratio: 5.53; Figure 4 ).
Validation of the MFC immunophenotypic-computerized algorithm in smoldering MM
We finally assessed if the MFC immunophenotypic-computerized classification model generated herein could maintain its significance in a different series of patients. For this purpose, we have faced 114 newly diagnosed smoldering MM patients, and classified them against the MGUS and symptomatic MM reference groups. Our results showed the expected heterogeneity that characterizes smoldering MM patients, with approximately half of the cases (51%) being plotted in the overlapping area between MGUS and symptomatic MM, 41 patients (36%) being classified as MGUS-like smoldering MM and the remaining 15 cases (13%) being assigned to the symptomatic MM reference group ( Figure 5 ). Smoldering MM patient stratified according to this model had different baseline clinical features (Supplementary  Table 1 ) and, importantly, it translated into markedly different TTP into active disease: median NR and 5% risk of progression at 2 years for MGUS-like smoldering MM cases; median of 108 months and 28% risk of progression for intermediate patients; and, finally, median TTP of 15 months and 53% risk of progression at 2 years for symptomatic MM-like smoldering MM patients.
DISCUSSION
There is increasing body of evidence that MM should no longer be considered as a single entity, [21] [22] [23] [24] [25] and similar to what occurs in other hematological malignancies, such as acute leukemias and non-Hodgkin lymphomas, different subtypes need to be recognized in order to define tailored therapies. Currently, (cyto)genetics is the most relevant tool used in MM to discriminate different risk categories, although this has not yet been translated into treatment adaptation. [26] [27] [28] The second relevant prognostic biomarker is response to therapy, CR being associated with longer survival; although this may guide consolidation and maintenance therapy decisions, there are subgroups of patients that do fall outside of the CR paradigm: those showing unsustained CR 12, 13 and those that do not achieve CR because they may have returned into an MGUS stage. How to Flow cytometric MGUS-like profile in myeloma B Paiva et al discriminate this latter subgroup of MM patients that would be associated with stable disease and prolonged survival, from resistant patients with suboptimal responses and the likelihood of progressive disease remains a challenge. This task should not be taken with lightness because these patients should be discriminated from true non-responders, and therapeutic decisions regarding further intensification and consolidation/ maintenance strategies should be taken accordingly. Here, he have strengthen MFC immunophenotyping using novel software analysis tools to develop an automated classification model capable of identifying newly diagnosed symptomatic MM patients with a baseline MGUS-like profile. This small subset (8% of all cases) shows an unprecedented TTP of 59% at 10 years, and its prognosis is not dependent on the depth of response achieved (CR vs no CR).
Long-term follow-up studies in the setting of HDT/ASCT are now showing that only a small fraction of MM patients (6-18%) remain X10-year-relapse free, and these are now considered as being operationally cured. [29] [30] [31] Some biomarkers have been proposed to identify patients with long-term survival, namely a gene expression profiling signature of MGUS (detected in B30% of patients) and the CD2 molecular subtype.
14 There is growing body of evidence showing that the risk of progression of MGUS, and particularly smoldering MM patients, into symptomatic MM can be predicted by using markers that evaluate the extent of tumor burden (for example, M-protein, marrow plasmacytosis, focal lesions by MRI or circulating PCs [32] [33] [34] [35] [36] [37] [38] ), or markers related to the level of clonal excess as reflected by the balance between normal and clonal PCs (for example, serum-free light or heavylight chains, immune paresis and clonal excess by MFC). Here, we postulated that the same principle could be inversely applied to symptomatic MM patients, in order to potentially identify a subgroup of MM patients with an MGUS-like profile. Based on PCA analysis of three easily accessible immunophenotypic variables (the relative frequency of BM PCs plus the percentage of clonal and normal PCs within the whole-BM PC compartment), here we propose a classification algorithm constructed through the analysis of a large number of MGUS and symptomatic MM patients, its results being graphically visualized with currently available MFC software (for example, APS). Based on the proposed algorithm, we identified 8% of symptomatic MM patients clustering outside of their reference group and together with typical MGUS cases. These patients presented with favorable baseline clinical features and less proliferative disease (which may be in accordance with a lower frequency of CD81 þ clonal PCs 43 ). In addition, their clinical (symptomatic) recognition appears to occur before the accumulation of early cytogenetic abnormalities such as del(13q) and IGH translocations. CR rates after HDT/ASCT were similar among the two groups, but TTP and OS were markedly superior among symptomatic MM patients with an MGUS-like profile; moreover, the outcome of these patients was not compromised by failure of achieving CR.
From a translational point of view, the identification of biomarkers that may help to guide therapeutic decisions is likely to become more and more important with the availability of new treatment protocols, particularly regarding intensity and duration of therapy. Ideally, such biomarkers should be accurate, easy to standardized and provide results in a timely and cost-effective way. In the present study, we adopted new analytic tools developed by the EuroFlow consortium 19 to build a reference data set of MGUS and MM patients based on MFC characterization of the PC compartment. Because it relies in more than 1000 patients and three immunophenotypic variables, outliers can potentially be more accurately identified. Accordingly, among MGUS patients only seven cases were 'misclassified' as MM but, interestingly, three have now evolved into symptomatic disease with an overall estimated risk at 10 years of 67%. This estimated rate of transformation is superior to that found in our own previous observations (56% for MGUS patients with 495% clonal PCs among total BM PCs) 42 and those found with PC counts by morphology (45%) 34 or serological markers such as the M-protein (415 g/l), 32 abnormal sFLCs, 40 or HLC-pair suppression. 41 Likewise, we also identified among smoldering MM patients a group of approximately one-third of cases showing a clinical course similar to MGUS (those SMM patients with an MGUS-like profile) and, conversely, a smaller group of 10% smoldering MM cases with a symptomatic MM-like profile (median frequency of BM PCs of 11%, and a balance between clonal and normal PCs of 99%-1%) and median TTP of only 15 months. These patients could probably be considered as having ultra-high risk of progression or 'early MM', 44 and, again, the computerized classification model here generated supersedes our own previous observations (median TTP of 34 months for SMM patients with 495% clonal PCs among total BM PCs), and matches recent results obtained by morphological PC counts above 60% 36, 45 and highly abnormal sFLC ratios. 36, 37 In summary, we have developed a MFC immunophenotypingbased classification algorithm capable of identifying newly diagnosed symptomatic MM patients with a baseline MGUS-like profile, which show long-term survival independent of CR achievement. The prospective identification of this signature may contribute to discriminate a suboptimal response that requires additional treatment from a residual 'MGUS-like component' that may remain stable without further treatment. In addition, the model also contributes to the identification of MGUS and smoldering MM patients at high risk of malignant transformation. Importantly, the reference data set and classification algorithm here developed can be equally built or shared across different myeloma centers.
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